Boston Scientific BSX 0.63 % increase; green up pointing triangle has struck a deal to buy medical-device maker Silk Road Medical for about $1.26 billion, adding a technology for stroke prevention ...

Boston Scientific BSX has delivered an impressive return over the past year, with shares rallying 40.5%. The performance outpaced the industry’s 14.3% gain and the S&P 500 composite’s 12.5% rise.

The Boston Globe Its stock is up 50 percent. Billion-dollar deals for breakfast. How did Boston Scientific get its mojo back? “It’s been a brick by brick, constant improvement, strengthening ...

Boston Scientific is up 10.7% since the beginning of the year, and at $98.92 per share, it is trading close to its 52-week high of $106.18 from February 2025.

Boston Scientific (BSX) ended the recent trading session at $90.53, demonstrating a -0.34% swing from the preceding day's closing price. This change lagged the S&P 500's 0.19% loss on the day ...

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ...

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.